Stock 1548 GENSCRIPT BIOTECH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genscript Biotech Corporation

Equities

1548

KYG3825B1059

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
11.02 HKD +2.42% Intraday chart for Genscript Biotech Corporation +5.56% -44.51%
Apr. 23 Multiply Labs and GenScript Biotech Corporation Collaborate to Automate Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing CI
Apr. 23 Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,262 2,842 9,299 6,731 5,400 2,990 - -
Enterprise Value (EV) 1 4,262 2,842 8,055 5,828 5,400 2,384 2,592 2,166
P/E ratio -43.4 x -13.5 x -25.8 x -29.4 x -56.1 x -32.3 x 65.3 x 8.7 x
Yield - - - - - - - -
Capitalization / Revenue 15.6 x 7.27 x 18.2 x 10.8 x 6.43 x 2.33 x 1.56 x 1.08 x
EV / Revenue 15.6 x 7.27 x 15.8 x 9.31 x 6.43 x 1.86 x 1.35 x 0.78 x
EV / EBITDA -42.7 x -16.4 x -25.4 x -15.6 x -16 x -12 x 34.4 x 5.72 x
EV / FCF -33.1 x -10.4 x -29.4 x -17.2 x - -6.88 x -27.1 x -39.6 x
FCF Yield -3.02% -9.61% -3.4% -5.81% - -14.5% -3.69% -2.53%
Price to Book - 3.15 x 10.5 x 6.65 x - 2.28 x 2.48 x 1.75 x
Nbr of stocks (in thousands) 1,875,939 1,953,283 2,101,341 2,115,207 2,123,163 2,124,053 - -
Reference price 2 2.272 1.455 4.425 3.182 2.543 1.408 1.408 1.408
Announcement Date 3/27/20 3/26/21 3/20/22 3/30/23 3/10/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 273.4 390.8 511.1 625.7 839.5 1,281 1,920 2,776
EBITDA 1 -99.94 -173.6 -317.3 -372.6 -337.1 -199.4 75.39 379
EBIT 1 -119.1 -203.9 -359.7 -436.8 -411 -258.2 -4.528 467
Operating Margin -43.57% -52.17% -70.38% -69.81% -48.96% -20.15% -0.24% 16.82%
Earnings before Tax (EBT) 1 -113.7 -281.9 -496.4 -431.7 -351 -244.9 35.84 673
Net income 1 -96.91 -204.9 -347.9 -226.9 -95.48 -102.8 27.95 389.4
Net margin -35.45% -52.44% -68.07% -36.26% -11.37% -8.02% 1.46% 14.03%
EPS 2 -0.0523 -0.1078 -0.1713 -0.1082 -0.0453 -0.0436 0.0216 0.1619
Free Cash Flow 1 -128.6 -273 -274.2 -338.7 - -346.5 -95.75 -54.73
FCF margin -47.06% -69.85% -53.65% -54.13% - -27.05% -4.99% -1.97%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/27/20 3/26/21 3/20/22 3/30/23 3/10/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - - - 281.5 391.3 448.2 645.4 650.1
EBITDA - - - - - - - -
EBIT 1 - - - - -220.2 - -14.5 -206.9
Operating Margin - - - - -56.27% - -2.25% -31.82%
Earnings before Tax (EBT) - -123.9 - -346.2 - - - -
Net income -113.1 -91.85 -91.12 -256.7 - - - -
Net margin - - - -91.21% - - - -
EPS 2 -0.0601 - -0.0461 - - - 0.0300 -0.0600
Dividend per Share - - - - - - - -
Announcement Date 8/30/20 3/26/21 8/23/21 3/20/22 9/26/23 3/10/24 - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - 1,245 903 - 606 398 824
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -129 -273 -274 -339 - -346 -95.8 -54.7
ROE (net income / shareholders' equity) -22.5% -31.9% -18.7% -16.3% - -8.9% -2.16% 18.2%
ROA (Net income/ Total Assets) - -17.5% -9.08% -7.02% - -3.53% 1.6% 5.3%
Assets 1 - 1,168 3,833 3,232 - 2,911 1,747 7,342
Book Value Per Share 2 - 0.4600 0.4200 0.4800 - 0.6200 0.5700 0.8000
Cash Flow per Share 2 - - -0.0700 -0.0600 - -0.0800 0.0300 0.4700
Capex 1 - 122 137 218 - 183 211 238
Capex / Sales - 31.19% 26.89% 34.91% - 14.29% 11.01% 8.58%
Announcement Date 3/27/20 3/26/21 3/20/22 3/30/23 3/10/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genscript Biotech Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.408 USD
Average target price
3.688 USD
Spread / Average Target
+162.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENSCRIPT BIOTECH CORPORATION Stock Genscript Biotech Corporation
-44.51% 2.99B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 1548 Stock
  4. Financials Genscript Biotech Corporation